Literature DB >> 7972297

Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole.

H Szechtman1, H Dai, S Mustafa, H Einat, R M Sullivan.   

Abstract

To assess whether the interval between injections affects the course of locomotor sensitization to quinpirole, groups of rats were injected every 2, 4, or 8 days with quinpirole (0, 0.025, 0.25, 0.5, and 2.5 mg/kg; n = 222) and their locomotor activity monitored after each injection for a total of 10 tests. Results indicate that the number of drug injections, rather than the interval between them, predominantly controls the development of locomotor sensitization to quinpirole. It is suggested that this may reflect a rapid induction but slow decay time for a response-enhancing factor stimulated by each injection of quinpirole, and that the effects of this putative factor are cumulative but saturable.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972297     DOI: 10.1016/0091-3057(94)90201-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  20 in total

1.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters.

Authors:  Julia A Chester; Amanda J Mullins; Chau H Nguyen; Val J Watts; Robert L Meisel
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

3.  Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments.

Authors:  Anna Dvorkin; Kirsten E Culver; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2006-05-11       Impact factor: 4.530

4.  Dopamine receptor-mediated regulation of neuronal "clock" gene expression.

Authors:  M Imbesi; S Yildiz; A Dirim Arslan; R Sharma; H Manev; T Uz
Journal:  Neuroscience       Date:  2008-11-05       Impact factor: 3.590

Review 5.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

6.  Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole.

Authors:  H Einat; D Einat; M Allan; H Talangbayan; T Tsafnat; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

7.  Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder(OCD): form and control.

Authors:  H Szechtman; M J Eckert; W S Tse; J T Boersma; C A Bonura; J Z McClelland; K E Culver; D Eilam
Journal:  BMC Neurosci       Date:  2001-04-12       Impact factor: 3.288

8.  Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism.

Authors:  H Szechtman; H Talangbayan; G Canaran; H Dai; D Eilam
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.

Authors:  Dimitris Kontis; Vasileios Boulougouris; Vasiliki Maria Papakosta; Stamatina Kalogerakou; Socrates Papadopoulos; Cornelia Poulopoulou; George N Papadimitriou; Eleftheria Tsaltas
Journal:  Psychopharmacology (Berl)       Date:  2008-07-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.